Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
How this was made
The 30-second read
Why it matters
Net effect is a sentiment reshuffle rather than a single fundamental shock. The most time-sensitive trading angle is Walmart’s downgrade ahead of its Aug. 20 earnings report; Apple’s downgrade is tied to guidance missing expectations; the rest are upgrades/initiations that can move short-term positioning but lack incremental disclosures in the text.
Market read
Traders can use the rating changes to adjust near-term positioning, but the article’s incremental information is limited because it mostly reports analyst opinions rather than new filings, trial readouts, or contract awards.
What to watch
For pre-earnings downgrades (Walmart) and guidance-miss framing (Apple), traders should watch for whether upcoming earnings confirm or contradict the analyst narrative, since the article provides no new guidance numbers.
Background
The piece is a multi-stock roundup of analyst rating changes and initiation notes, with a few items explicitly tied to recent earnings/guidance and one pre-earnings window (Walmart).
Ticker impact
Deutsche Bank upgraded Palantir to Buy from Hold, calling its Q2 report “exceptional” and keeping a $200 target.
Mildly positive bias for the next session(s) as traders price the upgrade; follow-through depends on broader tape.
This is a fresh rating change with an unchanged target, which typically moves sentiment, but the article provides no incremental Palantir operational or financial figures.
Oppenheimer upgraded Inspire Medical to Outperform, citing Q2 revenues of $201M slightly above estimates.
Moderately positive near-term drift, especially if the market had underweighted the Q2 beat.
The article includes a concrete Q2 revenue figure and a rating change, but lacks guidance details or new trial/regulatory events.
UBS upgraded BBB Foods to Buy from Neutral, highlighting same-store-sales ahead of inflation and value-seeking demand.
Slightly positive bias as the market re-rates the business quality narrative.
The thesis is qualitative in the article and does not add new company disclosures beyond the analyst’s interpretation.
Leerink upgraded Replimune to Outperform, stating high conviction the FDA will grant RP-1 plus nivolumab accelerated approval.
Potentially strong positive reaction if traders treat it as a signal on FDA timing.
The article provides no new clinical or regulatory filing details, only an analyst’s conviction statement.
Wolfe Research upgraded Madrigal Pharmaceuticals to Outperform, arguing shares overcorrected on stage 4 liver fibrosis timing concerns.
Mild-to-moderate positive near-term, contingent on how the market interprets the “overcorrected” claim.
No new trial results or regulatory updates are disclosed, so the catalyst is primarily sentiment and positioning.
Oppenheimer downgraded Walmart to Perform from Outperform ahead of its Aug. 20 earnings report, citing a less compelling near-term outperformance case.
Negative bias into the earnings date, with volatility risk around the Aug. 20 report.
The downgrade is time-relevant and explicitly tied to the pre-earnings window, but the article does not include new Walmart fundamentals.
China Renaissance downgraded Apple to Hold after in-line Q3 results and Q4 guidance that missed expectations.
Slightly negative near-term bias, especially if traders focus on guidance quality rather than results.
The article cites both the in-line results and the guidance miss, which are concrete drivers, though no new guidance numbers are provided.
Citizens downgraded eBay to Market Perform, arguing consensus estimates are too high.
Mild negative drift as the market reassesses expectations.
The article provides no specific revised estimates or new operational disclosures.
Market effects
Broad set of analyst rating actions across software, semis, and healthcare; can shift relative performance within AI infrastructure, cyber, and managed care baskets.
Limited. Most actions are US-listed names; SK Hynix coverage is a global memory-cycle signal.
Memory-cycle optimism (SK Hynix) and AI infrastructure sentiment (CoreWeave) can marginally influence broader AI and semiconductor risk appetite.
Counterpoint
Because this is largely analyst rating/coverage activity, the market may already price the consensus view; without new company disclosures, follow-through can fade quickly.
Key entities
- companyWalmart
Oppenheimer downgraded to Perform ahead of Aug. 20 earnings.
- companyPalantir
Deutsche Bank upgraded to Buy, citing exceptional Q2.
- companyApple
China Renaissance downgraded to Hold after in-line Q3 and Q4 guidance miss.
- companyCoreWeave
Piper Sandler initiated Overweight with a $151 target.
